WuXi PharmaTech (Cayman) Inc. is a leading global contract research and manufacturing organization that provides comprehensive services for the pharmaceutical, biotechnology, and medical device industries. The company specializes in a wide range of capabilities including drug discovery, development, and manufacturing, leveraging advanced technology and a diverse scientific workforce. With a strong focus on innovation and quality, WuXi PharmaTech aims to accelerate the process of transforming promising molecules into viable therapeutics, positioning itself as an essential partner in advancing global health solutions. Its extensive platform and strategic collaborations further enhance its competitive advantage in the rapidly evolving life sciences sector.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | 0.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | — |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | 0 |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
June has seen many ETF launches, from pure-play AI memory chip thematics to an autism impact fund that donates returns to nonprofits. With a record breaking 214 launches, the ETF landscape continues to expand into new markets.
